
	Three Months Ended
	(in thousands, except per share amounts)
	March 31,⁽¹⁾		June 30,⁽²⁾		September 30,⁽³⁾
	2012		2012		2012
	Restated		Restated		Restated			December 31,
	(Note 2)		(Note 2)		(Note 2)			2012
Net product sales	$	33,163	$	33,284	$	32,137		$	24,587
Promotion services revenue		7,905		8,085		8,556			8,552
Cost of product sales		5,532		5,664		5,474			5,326
Net income (loss)		9,665		11,228		(13,161)	⁽⁴⁾		1,888
Basic net income (loss) per share	$	0.17	$	0.20	$	(0.23)		$	0.03
Diluted net income (loss) per share	$	0.16	$	0.19	$	(0.23)		$	0.03


	Three Months Ended
	(in thousands, except per share amounts)
			June 30,⁽⁵⁾⁽⁶⁾		September 30,⁽⁷⁾		December 31,⁽⁸⁾
			2011		2011		2011
	March 31,		Restated		Restated		Restated
	2011		(Note 2)		(Note 2)		(Note 2)
Net product sales	$	21,662	$	26,207	$	32,310	$	31,772
Promotion services revenue		—		5,719		6,992		7,903
Cost of product sales		3,103		4,205		6,262		5,839
Net income		3,849		1,891		10,832		11,550
Basic net income per share	$	0.08	$	0.03	$	0.19	$	0.20
Diluted net income per share	$	0.08	$	0.03	$	0.18	$	0.19

(1)	For the three months ended March, 2012, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.9 million, $0.6 million and $1.0 million, respectively, and increasing basic and diluted earnings per share by $0.02 and $0.01, respectively.

(2)	For the three months ended June 30, 2012, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.1 million, $0.4 million and $0.6 million, respectively, and increasing basic and diluted earnings per share by $0.01.

(3)	For the three months ended September 30, 2012, the restatement revisions had an impact of increasing revenues, decreasing cost of product sales, and increasing net income by $7,000, $1,000 and $0.4 million, respectively, and increasing basic and diluted earnings per share by $0.01.

(4)

During the three months ended September 30, 2012, the Company identified an impairment indicator with respect to its intangible assets related to its promotion and distribution contract rights and recorded losses of approximately $42.7 million to recognize the full impairment and recorded a benefit for income tax of approximately $6.8 million due to the impairment of intangible assets, which resulted in a reversal of deferred tax liabilities. This was partially offset by the impact of recognizing a full valuation allowance on any remaining NovaMed deferred tax assets. In addition, for the same period, the Company recorded a non-cash gain of $12.8 million, primarily related to the decrease in estimated probability of achieving targets relating to NovaMed’s product distributor agreements, including the renewal of the agreement with Sanofi for a five-year term.

(5)	For the three months ended June 30, 2011, the restatement revisions had an impact of decreasing revenues, cost of product sales, and net income by $1.2 million, $1.0 million and $0.1 million, respectively, and decreasing diluted earnings per share by $0.01.

(6)	On April 18, 2011, SciClone acquired NovaMed. Commencing April 18, 2011, the Company’s financial statements include the assets, liabilities, operating results and cash flows of NovaMed.

(7)	For the three months ended September 30, 2011, the restatement revisions had an impact of increasing revenues, cost of product sales, and net income by $1.9 million, $1.2 million and $0.6 million, respectively, and increasing basic and diluted earnings per share by $0.01.

(8)	For the three months ended December 31, 2011, the restatement revisions had an impact of decreasing revenues, cost of product sales, and net income by $1.8 million, $0.9 million, and $0.9 million, respectively, and decreasing basic and diluted earnings per share by $0.01 and $0.02, respectively.

The following table presents the impact of the revisions on the Company’s previously issued selected quarterly financial data for the three months ended December 31, 2011 (in thousands):


	For the Three Months Ended
	December 31, 2011
	As Reported		As Restated⁽⁹⁾

Net product sales	$	33,543	$	31,772
Cost of product sales		6,712		5,839
Net income		12,402		11,550
Basic net income per share	$	0.21	$	0.20
Diluted net income per share	$	0.21	$	0.19

(9)	Changes to the selected quarterly financial data for the three months ended December 31, 2011 mainly related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.